Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul;19(3):96-100.
doi: 10.4103/0971-4065.57105.

Is soluble transferrin receptor a good marker of iron deficiency anemia in chronic kidney disease patients?

S Gupta  1 , B Uppal, B Pawar
Affiliations

Is soluble transferrin receptor a good marker of iron deficiency anemia in chronic kidney disease patients?

S Gupta et al. Indian J Nephrol. 2009 Jul.

Abstract

Anemia in patients with chronic renal failure is multifactorial with an absolute or functional iron deficiency present in 60-80% of patients. In this study, 102 patients of stage 5 chronic kidney disease (CKD) were enrolled. Thirty six age- and sex-matched anemic patients without any known renal disease were taken as controls. Their sTfR levels were measured with anemia profile.(Fe, TIBC, Ferritin, TSAT). The patients were followed up twice, at four weeks and six months. There was a significant statistical difference in the mean sTfR levels in patients when compared to controls (P < 0.01).The mean level of sTfR in CKD patients was 3.23 +/- 2.07 mg/l while in controls this was 5.16 +/- 3.64 mg/l. sTfR had no statistically significant correlation with the levels of hemoglobin, iron, ferritin, TIBC and TSAT. We conclude that owing to complexity of iron metabolism in CKD, sTfR can not be used as a reliable marker of iron deficiency anemia.

Keywords: Chronic kidney disease; erythropoietin; hemodialysis; iron deficiency anemia; soluble transferrin receptor; total iron binding capacity; transferrin saturation.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Agarwal SK. Chronic kidney disease and its prevention in India. Kidney Int Suppl. 2005;98:S41–5. - PubMed
    1. National Kidney Foundation. Kidney Disease outcomes quality initiative: clinical practice guidelines for anemia of chronic kidney disease. IV NKF-K / DOQI, Update 2000. Am J Kidney Dis. 2001;37:S182–238. - PubMed
    1. Ahluwalia N, Skikne BS, Savin V, Chonko A. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis. 1997;30:532–41. - PubMed
    1. Baillie FJ, Morrison AE, Fergus I. Soluble transferrin receptor: a discriminating assay for iron deficiency. Clin Lab Haematol. 2003;25:353–57. - PubMed
    1. Miller YE, Jones C, Scoggin C, Morse H, Seligman P. Chromosome 3q (22-ter) encodes the human transferrin receptor. Am J Hum Genet. 1983;35:573–83. - PMC - PubMed